Evidence map›Paper›PMID 36845546›Full record

ArticleFrontiers in molecular biosciences2023

Structural and functional properties of the Kunitz-type and C-terminal domains of Amblyomin-X supporting its antitumor activity.

K L P Morais, L Ciccone, E Stura, M P Alvarez-Flores, G Mourier, M Vanden Driessche, J M Sciani, A Iqbal, S P Kalil, G J Pereira and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

K L P MoraisCenter of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo, Brazil.
L CicconeDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA SIMoS, Gif-sur-Yvette, France.
E SturaDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA SIMoS, Gif-sur-Yvette, France.
M P Alvarez-FloresCenter of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo, Brazil.
G MourierDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA SIMoS, Gif-sur-Yvette, France.
M Vanden DriesscheDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA SIMoS, Gif-sur-Yvette, France.
J M ScianiCenter of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo, Brazil.
A IqbalCenter of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo, Brazil.
S P KalilCenter of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo, Brazil.
G J PereiraDepartment of Pharmacology, Federal University of São Paulo, São Paulo, Brazil.
R Marques-PortoLaboratory of Development and Innovation, Butantan Institute, São Paulo, Brazil.
P CunegundesCenter of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo, Brazil.
L JulianoDepartment of Biophysics, Federal University of São Paulo, São Paulo, Brazil.
D ServentDépartement Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA SIMoS, Gif-sur-Yvette, France.
A M Chudzinski-TavassiCenter of Excellence in New Target Discovery (CENTD), Butantan Institute, São Paulo, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amblyomin-X is a Kunitz-type FXa inhibitor identified through the transcriptome analysis of the salivary gland from

Indexed as

Amblyomin-Xantitumor drug candidateendocytosishigh content imaging (HCI)proteasome inhibitorprotein crystallizationTFPI-like

Identifiers

PMID36845546
PMCPMC9948614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.